“An unprecedented orientation efficiency of 98.3% for non-ambiguous lineage cases was shown for the [EuroFlow] ALOT combination with a series of 483 newly diagnosed acute leukemia cases, tested prospectively at different centers.”1*
Results from the clinical trial (BD OneFlow™ ALOT Instruction For Use) showed that the BD OneFlow™ ALOT gave an overall agreement of 100% (93 of 93) in orienting patients into lymphoid (44 of 44 concordant) and non-lymphoid (49 of 49 concordant) lineages when compared with the EuroFlow system. Furthermore, interpretation of clinical trial results using the BD OneFlow™ Solution was highly concordant to diagnostic truth derived from a composite of patient history and lab findings.